Page 0098

DISEASE-SPECIFIC CANCER CONTROL

CANCER CONTROL 2014 97

References

1. UNAIDS 2012. Global AIDS Response Progress Report. 2012. Zimbabwe Country

Report. Available at: http://www.unaids.org/en/dataanalysis/knowyourresponse/

countryprogressreports/2012countries/ce_ZW_Narrative_report.pdf.

2. Baeten JM, Chohan BH, Lavreys L et al. Correlates of human herpesvirus 8

seropositivity among heterosexual men in Kenya. AIDS 2002; 16:2073-8. PMID:

12370507

3. Eltom MA, Mbulaiteye SM, Dada AJ, Whitby D, and Biggar RJ. Transmission of human

herpesvirus 8 by sexual activity among adults in Lagos, Nigeria. AIDS 2002; 16:2473-8.

PMID: 12461423

4. Lavreys L, Chohan B, Ashley R et al. Human herpesvirus 8: Seroprevalence and

correlates in prostitutes in Mombasa, Kenya. J Infect Dis 2003; 187:359-63. PMID:

12552419

5. Klaskala W, Brayfield BP, Kankasa C et al. Epidemiological characteristics of human

herpesvirus-8 infection in a large population of antenatal women in Zambia. J Med Virol

2007; 75:93-100. PMID: 15543582

6. Olsen SJ, Chang Y, Moore PS, Biggar RJ, and Melbye M. Increasing Kaposi's sarcomaassociated herpesvirus seroprevalence

with age in a highly Kaposi's sarcoma endemic

region, Zambia in 1985. AIDS 1998; 12:1921-5. PMID: 9792393

7. Newton R, Ziegler J, Bourboulia D et al. The seroepidemiology of Kaposi's sarcomaassociated herpesvirus (KSHV/HHV-8)

in adults with cancer in Uganda. Int J Cancer

2003; 103:226-32.

8. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS

in the United States 1980 - 2002. AIDS 2006;20:1645-54. PMID 16868446

9. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults

accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008;

22:1897-908. PMID: 18784453

10.zachariah R, Fitzgerald M, Massaquoi M, Pasulani O, Arnould L, Makombe S, et al. Risk

factors for high early mortality in patients on antiretroviral treatment in a rural district

of Malawi. AIDS 2006; 20:2355-2360. PMID: 17117022

11.castelnuovo B, Manabe YC, Kiragga A, Kamya M, Easterbrook P, Kambugu A. Causespecific mortality and the contribution of immune reconstitution inflammatory

syndrome in the first 3 years after antiretroviral therapy initiation in an urban African

cohort. Clin Infect Dis. 2009; 49:965-72. PMID: 19673615

12.http://www.unaids.org/globalreport/global_report.htm

13.campbell TB, Borok M, Ndemera B, Fiorillo S, White IE, Zhang XQ, Machekano R,

Katzenstein D, Gwanzura L. Lack of Evidence for Frequent Heterosexual Transmission

of Human Herpesvirus 8 (HHV-8) in Zimbabwe. Clin Infect Dis 2009;48:1601-8.

PMCID: PMC2720069

14.chokunonga E, Levy LM, Bassett MT, Borok MZ, Mauchaza BG, Chirenje ZM, Parkin

DM, AIDS and cancer in Africa: The evolving epidemic in Zimbabwe. AIDS 1999;

13:2583-2588. PMID 10630528

15.gondos A, Chokunonga E, Brenner H, Parkin DM, Sankila R, Borok M, Chirenje ZM,

Nyakabau AM, Bassett MT. Cancer Survival in a Southern African Urban Population.

Int J Cancer 2004;112:860-864. PMID 15386382

16.boffi El Amari, Toutous-Trellu L, Gayet-Ageron A, Baumann M, Cathomas G, Steffen I,

Erb P, Mueller NJ, Furrer H, Cavassini M, Vernazza P, Hirsch HH, Bernasconi E, Hirschel

B, the Swiss HIV Cohort Study. Predicting the evolution of Kaposi sarcoma, in the

highly active antiretroviral era. AIDS 2008; 22:1019-28. PMID: 18520345

17.martin-Carbonero L, Barrios A, Saballs P, Sirera G, Santos J, Palacios R, Eulalio Valencia

M, Alegre M, Podzamczer, D., Gonzalez-Lahoz J, and the Caelyx/KS Spanish Study

Group. Pegylated liposomal doxorubicin plus highly active antiretroviral therapy

versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma.

AIDS 2004; 18:1737-40. PMID: 15280789

18.lichterfeld M, Qurishi N, Hoffmann C, Hochdorfer B, Brockmeyer NH, Arasteh K,

Mauss S, Rockstroh JK, German Clinical AIDS Working Group. Treatment of HIV-1-

associated Kaposi's sarcoma with pegylated liposomal doxorubicin and HAART

simultaneously induces effective tumor remission and CD4+ T cell recovery. Infection

2004; 33:140-147. PMID: 15940415

19.cooley T, Henry D, Tonda M, Sun S, O'Connell M, Rackoff W. A randomized doubleblind study of pegylated liposomal doxorubicin

for the treatment of AIDS-related

Kaposi's sarcoma. Oncologist 2007; 12:114-23. PMID: 17227906

20.nguyen HQ, Magaret AS, Kitahat MM, Van Rompaey SE, Wald A, Casper C. Persistent

Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the

predictors of clinical response. AIDS 2008; 22:937-45. PMCID: PMC2730951

21.martin-Carbonero L, Palacios R, Valencia E, Saballs P, Sirera G, Santos I, Baldobi F,

Alegre M, Goyenechea A, Pedreira J, Gonzalez del Castillo J, Martinez- Lacasa J,

Ocampo A, Alsina M, Santos J, Podzamczer D, Gonzalez-Lahoz J, Caelyx/Kaposi's

Sarcoma Spanish Group. Long-term prognosis of HIV-infected patients with Kaposi

sarcoma treated with pegylated liposomal doxorubicin. Clin Infect Dis 2008; 47:410-

417. PMID: 18582203

22.borok M, Fiorillo S, Gudza I, Putnam B, Ndemera B, White IE, Watson H, Gwanzura L,

Schooley RT, Campbell TB. Evaluation of plasma human Herpesvirus 8 DNA as a

marker of clinical outcomes during antiretroviral therapy of AIDS-related Kaposi

sarcoma in Zimbabwe. Clin Infect Dis. 2010; 51:342-349. PMID: 20572760

23.M. Borok, unpublished data

24.makombe SD, Harries AD, Yu JK-L, Hochgesang M, Mhango E, Weigel R, Pasulani O,

Fitzgerald M, Schouten EJ, Libamba E. Outcomes of patients with Kaposi sarcoma who

start antiretroviral therapy under routine programme conditions in Malawi. Tropical

Doctor. 2008; 385-7. PMID: 18302849

25.nelson BC, Borok MB, Makadzange T, Mhlanga T, Campbell TB. AIDS-related Kaposi

sarcoma: Outcomes after initiation of highly active antiretroviral therapy under

routine conditions in Zimbabwe. International Conference on AIDS Malignancies and

Opportunistic Infections. Bethesda, 2010.

26.http://www.who.int/cancer/palliative/definition/en/

27.peter A. Selwyn, Mimi Rivard. Palliative Care for AIDS: Challenges and Opportunities

in the Era of Highly Active Anti-Retroviral Therapy. Journal of Palliative Medicine. June

2003, 6(3): 475-487. PMID: 14509497

28.sepúlveda C, Marlin A, Yoshida T, Ullrich A. Palliative Care: The World Health

Organization's Global Perspective. Vol. 24 No. 2 August 2002 J Pain and Symptom

Manage. PMID: 12231124

29.brown CA, Lilford RJ. The stepped wedge trial design: a systematic review. BMC

Medical Research Methodology 2006; 6:54 doi:10.1186/1471-2288-6-54. PMID:

17092344

30.borok M, Fiorillo S, Gudza I, Putnam B, Ndemera B, White IE, Watson H, Gwanzura L,

Schooley RT, Campbell TB. Evaluation of plasma human Herpesvirus 8 DNA as a

marker of clinical outcomes during antiretroviral therapy of AIDS-related Kaposi

sarcoma in Zimbabwe. Clin Infect Dis 2010; 51:342-349. PMID: 20572760

and clinical research in the epidemiology and treatment of AIDSKS. She and Dr Campbell are

currently collaborating in two

randomized clinical trials, funded by NIAID and NCI through the

AIDS Clinical Trials Group and the AIDS Malignancy Consortium.

Dr Thomas Campbell has significant experience in clinical and

translational investigation of HIV/AIDS and AIDS-KS in African

settings that are highly relevant to the aims of this project.

Dr James Hakim, FRCP is an internist and clinical epidemiologist

with broad exposure to a wide spectrum of communicable and non-communicable diseases seen in sub-Saharan Africa.

Dr Jean Kutner is an experienced clinician/geriatrician. She is an

innovative researcher in the field of palliative care.

Dr Samantha MaWhinney, ScD is Professor of statistics and

currently Programme Director of the Department of Biostatistics

and Informatics in the Colorado School of Public Health.

Dr Eric Simoes has a broad background in infectious diseases with

specific training and expertise in epidemiology, and development

and assessment of WHO guidelines.

Index

  1. Page 0001
  2. Page 0002
  3. Page 0003
  4. Page 0004
  5. Page 0005
  6. Page 0006
  7. Page 0007
  8. Page 0008
  9. Page 0009
  10. Page 0010
  11. Page 0011
  12. Page 0012
  13. Page 0013
  14. Page 0014
  15. Page 0015
  16. Page 0016
  17. Page 0017
  18. Page 0018
  19. Page 0019
  20. Page 0020
  21. Page 0021
  22. Page 0022
  23. Page 0023
  24. Page 0024
  25. Page 0025
  26. Page 0026
  27. Page 0027
  28. Page 0028
  29. Page 0029
  30. Page 0030
  31. Page 0031
  32. Page 0032
  33. Page 0033
  34. Page 0034
  35. Page 0035
  36. Page 0036
  37. Page 0037
  38. Page 0038
  39. Page 0039
  40. Page 0040
  41. Page 0041
  42. Page 0042
  43. Page 0043
  44. Page 0044
  45. Page 0045
  46. Page 0046
  47. Page 0047
  48. Page 0048
  49. Page 0049
  50. Page 0050
  51. Page 0051
  52. Page 0052
  53. Page 0053
  54. Page 0054
  55. Page 0055
  56. Page 0056
  57. Page 0057
  58. Page 0058
  59. Page 0059
  60. Page 0060
  61. Page 0061
  62. Page 0062
  63. Page 0063
  64. Page 0064
  65. Page 0065
  66. Page 0066
  67. Page 0067
  68. Page 0068
  69. Page 0069
  70. Page 0070
  71. Page 0071
  72. Page 0072
  73. Page 0073
  74. Page 0074
  75. Page 0075
  76. Page 0076
  77. Page 0077
  78. Page 0078
  79. Page 0079
  80. Page 0080
  81. Page 0081
  82. Page 0082
  83. Page 0083
  84. Page 0084
  85. Page 0085
  86. Page 0086
  87. Page 0087
  88. Page 0088
  89. Page 0089
  90. Page 0090
  91. Page 0091
  92. Page 0092
  93. Page 0093
  94. Page 0094
  95. Page 0095
  96. Page 0096
  97. Page 0097
  98. Page 0098
  99. Page 0099
  100. Page 0100
  101. Page 0101
  102. Page 0102
  103. Page 0103
  104. Page 0104
  105. Page 0105
  106. Page 0106
  107. Page 0107
  108. Page 0108
  109. Page 0109
  110. Page 0110
  111. Page 0111
  112. Page 0112
  113. Page 0113
  114. Page 0114
  115. Page 0115
  116. Page 0116
  117. Page 0117
  118. Page 0118
  119. Page 0119
  120. Page 0120
  121. Page 0121
  122. Page 0122
  123. Page 0123
  124. Page 0124
  125. Page 0125
  126. Page 0126
  127. Page 0127
  128. Page 0128
  129. Page 0129
  130. Page 0130
  131. Page 0131
  132. Page 0132
  133. Page 0133
  134. Page 0134
  135. Page 0135
  136. Page 0136
  137. Page 0137
  138. Page 0138
  139. Page 0139
  140. Page 0140
  141. Page 0141
  142. Page 0142
  143. Page 0143
  144. Page 0144
  145. Page 0145
  146. Page 0146
  147. Page 0147
  148. Page 0148
  149. Page 0149
  150. Page 0150
  151. Page 0151
  152. Page 0152
  153. Page 0153
  154. Page 0154
  155. Page 0155
  156. Page 0156

powered by PageTiger